文献速递前列腺癌

耻骨后根治性前列腺切除术后早期与晚期生化复发的病因学与管理

Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.
PubMed 文献 · BJU Int · 2017-03-14

该研究纳入2000年10月至2009年10月间接受开放耻骨后根治性前列腺切除术的1597例男性,比较术后5年内早期与5年后晚期生化复发的特征与管理。5年内和10年内生化复发概率分别为12.3%(95%CI 10.7-13.9)和18.4%(95%CI 16.2-20.6);早期复发组更多接受挽救性放疗(80.8% vs 59%)和雄激素剥夺治疗(14.6% vs 8.2%),晚期复发组更多接受主动监测(32.8% vs 4.6%;P<0.001)。挽救性放疗反应与复发时间无关。

要点

  • 术后5年内和10年内生化复发概率分别为12.3%和18.4%。
  • 早期复发组接受挽救性放疗80.8% vs 晚期组59%,接受雄激素剥夺治疗14.6% vs 8.2%。
  • 晚期复发组接受主动监测32.8% vs 早期组4.6%(P<0.001)。

核心结论

  • 约三分之一的生化复发发生在根治性前列腺切除术后5至10年。
  • 生化复发的病因学与管理取决于复发时间,而挽救性放疗反应与复发时间无关。
  • 所有根治性前列腺切除术后男性必须进行5年以上的长期随访。

研究设计与样本

  • 2000年10月至2009年10月间1597例接受开放耻骨后根治性前列腺切除术的男性。
  • 生化复发采用挽救性放疗、雄激素剥夺治疗或主动监测管理。
  • 采用Kaplan-Meier分析评估无生化复发生存,采用logistic回归和Cox比例风险模型分别评估预测早期或晚期生化复发及挽救性放疗后生化复发的因素。

主要发现

  • 5年内和10年内发生生化复发的概率分别为12.3%(95%CI 10.7-13.9)和18.4%(95%CI 16.2-20.6)。
  • 多因素分析中,前列腺特异性抗原倍增时间、手术切缘阳性和病理Gleason评分显著区分早期与晚期生化复发。
  • 发生生化复发的男性中,74.5%接受挽救性放疗、12.7%接受雄激素剥夺治疗、12.7%接受主动监测。
  • 早期复发组接受挽救性放疗比例显著更高(80.8% vs 59%),接受雄激素剥夺治疗比例也显著更高(14.6% vs 8.2%);晚期复发组接受主动监测比例显著更高(32.8% vs 4.6%;P<0.001)。
  • 挽救性放疗反应与生化复发时间无关;多因素分析中,临床分期和病理分期显著预测挽救性放疗失败。

临床怎么用

  • 作者结论指出,所有根治性前列腺切除术后男性必须进行5年以上的长期随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine the characteristics and management of earlier (within 5 years) vs later (after 5 years) biochemical recurrence (BCR) after radical prostatectomy (RP). MATERIALS AND METHODS: Between October 2000 and October 2009, 1597 men underwent open retropubic RP. BCRs were managed using salvage radiation therapy (SRT), androgen deprivation therapy (ADT) or active surveillance (AS). BCR-free survival was assessed using Kaplan-Meier analysis. Factors predicting earlier or later BCR and BCR after SRT were assessed using logistic regression and Cox proportional hazard models, respectively. RESULTS: The probabilities of developing BCR within 5 years and 10 years were 12.3% (95% confidence interval [CI] 10.7-13.9) and 18.4% (95% CI 16.2-20.6), respectively. On multivariate analysis, prostate-specific antigen doubling time, positive surgical margins and pathological Gleason score significantly differentiated earlier from later BCR. Overall, 74.5, 12.7 and 12.7% of men developing BCR underwent SRT, ADT or AS, respectively. A significantly greater proportion of men in the earlier BCR group underwent SRT (80.8 vs 59%) and ADT (14.6 vs 8.2%), and a significantly greater proportion of men in the later BCR group underwent AS (32.8 vs 4.6%; P<0.001). The response to SRT was independent of time to BCR. On multivariate analysis, clinical stage and pathological stage significantly predicted failure of SRT. CONCLUSIONS: Approximately one third of BCRs occurred between 5 and 10 years after RP. The aetiology and management of BCR was dependent on time to BCR, whereas response to SRT was independent of time to recurrence. Long-term follow-up is mandatory beyond 5 years for all men after RP.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Llukani E, Lepor H. Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy. BJU Int. 2017. PMID: 28220652. doi:10.1111/bju.13816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。